Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra 11:35:07 2024-05-17 am EDT After market 03:58:00 pm
27.94 EUR -2.03% Intraday chart for Fresenius SE & Co. KGaA 28.08 +0.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
What does the new atlas mean for the 'hospital jungle'? DP
Moody’s Revises Outlook on Fresenius Medical Care to Stable from Negative MT
Launch of new quality atlas for hospitals DP
Moody’s Affirms Fresenius' Rating, Outlook on Improving Profitability MT
Union demands Lauterbach approach the federal states on hospital reform DP
Dobrindt demands approach to federal states on hospital reform DP
Lauterbach's 'revolution' for clinics on the way DP
Cabinet launches hospital reform DP
Cabinet to get hospital reform underway DP
FRESENIUS SE : Receives a Buy rating from DZ Bank ZD
FRESENIUS SE : Jefferies reiterates its Buy rating ZD
Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank... Our Logo
FRESENIUS SE : Barclays gives a Buy rating ZD
FRESENIUS SE : Berenberg gives a Buy rating ZD
Fresenius Medical sees up to 2% US dialysis growth by year-end RE
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3% MT
FRESENIUS : Preparing for a strong(er) future performance Alphavalue
FRESENIUS SE : Deutsche Bank keeps its Buy rating ZD
Health Care Slips as Defensive Investors Rotate to Utilities - Health Care Roundup DJ
Home REIT cuts borrowings, Genflow shares restored AN
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading MT
Fresenius becomes more optimistic thanks to subsidiary Kabi - exit from Vamed DP
UBS rates Fresenius SE as 'Buy' - Target 34 euros DP
Dpa-AFX Overview: COMPANIES from 08.05.2024 - 15:15 DP
FRESENIUS SE : Berenberg reiterates its Buy rating ZD
Chart Fresenius SE & Co. KGaA
More charts
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
28.52 EUR
Average target price
36.41 EUR
Spread / Average Target
+27.65%
Consensus
  1. Stock Market
  2. Equities
  3. FRE Stock
  4. News Fresenius SE & Co. KGaA
  5. Fresenius to Sell 67% of Vamed's Rehabilitation Business to PAI Partners
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW